Hypoglycemia and Glucagon

Hypoglycemia occurs when plasma glucose drops below 70 mg/dL (3.9 mM). Healthy individuals normally maintain blood glucose levels above 80 mg/dL through a well-adapted neuroendocrine counterregulatory system. This threshold is clinically significant because symptoms typically manifest when glucose reaches 60-70 mg/dL, requiring prompt intervention to prevent severe complications.

Hypoglycemia primarily results from diabetes treatment, pancreatic tumors producing excess insulin, and glucose-lowering agents used in non-diabetic individuals. Insulin therapy poses the greatest risk, with contributing factors including insulin dose mismatches, increased insulin sensitivity, and concurrent conditions such as adrenal or pituitary insufficiency. In diabetic patients, the glucagon secretory response may become deficient over time, further increasing severe hypoglycemia risk.

Hypoglycemia manifests as sweating, hunger, confusion, paresthesias, palpitations, tremors, and anxiety when plasma glucose reaches 60-70 mg/dL. Severe hypoglycemia can progress to neurological symptoms, seizures, loss of consciousness, and coma. These autonomic and neuroglycopenic symptoms require immediate recognition and treatment to prevent life-threatening complications.

Recombinant glucagon interacts with the glucagon GPCR on target cells, activating the Gs-cAMP-PKA signaling pathway to rapidly increase blood glucose. It is administered intravenously, intramuscularly, or subcutaneously, with the intramuscular route preferred during emergencies. Following the initial glucagon response, patients must consume oral glucose or food to prevent recurrent hypoglycemia and maintain stable glucose levels.

Hypoglycemia treatment depends on severity and patient ability to consume food. Oral glucose is the first-line approach for conscious patients. Intravenous glucose can be administered under medical supervision when oral intake is not feasible. For severe hypoglycemic reactions when patients cannot take oral glucose, recombinant glucagon is the emergency treatment of choice.

Home glucose monitoring is crucial for documenting hypoglycemia episodes, enabling timely intervention and appropriate management decisions. Regular monitoring helps identify patterns and risk factors, particularly in diabetic patients at high risk of severe hypoglycemia. This proactive approach allows patients and healthcare providers to adjust treatment regimens and prevent life-threatening hypoglycemic events.

The initial response to hypoglycemia involves reducing endogenous insulin secretion, followed by releasing counterregulatory hormones including epinephrine, norepinephrine, glucagon, growth hormone, and cortisol. These hormones work together to raise blood glucose and restore glucose homeostasis. In diabetic patients with prolonged disease, the glucagon response may become deficient, compromising this critical defense mechanism.